PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
495.53%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.79%. Joel Greenblatt would see it as a clear outperformance relative to peers.
23.54%
D&A growth of 23.54% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
200.89%
Deferred tax growth of 200.89% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would see a difference that might matter for future cash flow if significant.
-14.46%
SBC declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
-67.75%
Working capital is shrinking yoy while Drug Manufacturers - Specialty & Generic median is -14.96%. Seth Klarman would see an advantage if sales remain robust.
-89.90%
AR shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage in working capital if sales do not drop.
-34.78%
Inventory shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a working capital edge if sales hold up.
-71.73%
AP shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
2.70%
Growth of 2.70% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
-842.63%
Other non-cash items dropping yoy while Drug Manufacturers - Specialty & Generic median is -2.60%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-128.34%
Negative CFO growth while Drug Manufacturers - Specialty & Generic median is -19.55%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
6.98%
CapEx growth of 6.98% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
83.74%
Acquisition growth of 83.74% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or partial deals fueling that difference.
-179.19%
Investment purchases shrink yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a short-term cash advantage if no high-return opportunities are missed.
-11.40%
We liquidate less yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a firm-specific hold strategy unless missed gains exist.
-2356.01%
We reduce “other investing” yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a potential advantage in preserving cash if top-line growth is not harmed.
3.89%
Investing flow of 3.89% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
99.52%
Debt repayment growth of 99.52% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.